INT273471

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.34
First Reported 2009
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 7
Total Number 9
Disease Relevance 9.20
Pain Relevance 1.10

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleoplasm (PTBP1) mRNA processing (PTBP1) nucleolus (PTBP1)
RNA binding (PTBP1) nucleus (PTBP1)
Anatomy Link Frequency
plasma 1
PTBP1 (Homo sapiens)
Pain Link Frequency Relevance Heat
agonist 24 91.92 High High
Inflammation 18 88.96 High High
pruritus 18 82.56 Quite High
Pain 45 78.80 Quite High
Bioavailability 6 78.48 Quite High
backache 6 71.04 Quite High
Dysuria 6 64.80 Quite High
depression 6 59.52 Quite High
abdominal pain 6 56.28 Quite High
nud 6 55.64 Quite High
Disease Link Frequency Relevance Heat
Premature Birth 582 100.00 Very High Very High Very High
Infection 57 99.72 Very High Very High Very High
Pre-term Labor 159 99.48 Very High Very High Very High
Death 12 98.90 Very High Very High Very High
Chorioamnionitis 9 98.00 Very High Very High Very High
Reprotox - General 3 18 97.50 Very High Very High Very High
Reprotox - General 1 6 90.32 High High
INFLAMMATION 18 88.96 High High
Vomiting 33 85.60 High High
Recurrence 18 84.32 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
From their data, the authors concluded that for the women with earliest previous spontaneous PTB at 20–27.9 weeks and 28–33.9 weeks, 4.7 and 4.6 women (respectively for each group) would need to be treated with 17OHP-C to prevent one PTB.
Negative_regulation (prevent) of PTB associated with premature birth
1) Confidence 0.34 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2697509 Disease Relevance 0.79 Pain Relevance 0
We believe that there is a place for progesterone in the prevention of PTB.
Negative_regulation (prevention) of PTB associated with premature birth
2) Confidence 0.34 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2697509 Disease Relevance 0.38 Pain Relevance 0
Another noteworthy point is that although the Meis et al study104 demonstrated a statistically significant reduction in the primary endpoint of PTB prior to 37 weeks’ gestation, the reduction in PTBs prior to 35 weeks and prior to 32 weeks’ gestation which are better surrogates for significant neonatal morbidity and mortality, were not statistically persuasive.
Negative_regulation (reduction) of PTB associated with premature birth
3) Confidence 0.25 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2697509 Disease Relevance 0.91 Pain Relevance 0
Oral progesterone has not been used for prevention of PTB because of its first-pass hepatic metabolism, lack of efficacy data, high side-effect profile, extreme variability in plasma concentrations.
Negative_regulation (prevention) of PTB in plasma associated with premature birth
4) Confidence 0.25 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2697509 Disease Relevance 0.24 Pain Relevance 0.10
Our retrospectively study110 showed infrequent spontaneous abortion at <24 weeks’ gestation (0.9%), stillbirth (0.5%), and neonatal death (0.4%) in women receiving progesterone prophylaxis to prevent PTB.
Negative_regulation (prevent) of PTB associated with reprotox - general 3, premature birth and death
5) Confidence 0.25 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2697509 Disease Relevance 3.22 Pain Relevance 0.85
In a multinational double blind placebo controlled trial on the use of bioadhesive progesterone vaginal gel for the prevention of PTB in 611 women,106 the findings revealed no significant differences between the progesterone vaginal gel and placebo in the rate of PTB at <35 weeks’ gestation (Table 1).
Negative_regulation (prevention) of PTB associated with premature birth
6) Confidence 0.22 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2697509 Disease Relevance 0.86 Pain Relevance 0
The role of antibiotics for the prevention of PTB in women in SPTL remains unproven, but this should not be confused with prophylactic antibiotics given to women with abnormal genital tract colonization in early pregnancy.
Negative_regulation (prevention) of PTB associated with pre-term labor
7) Confidence 0.17 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2861440 Disease Relevance 0.73 Pain Relevance 0.03
The role of atosiban for the prevention of PTB in women with SPTL without subclinical IAI, and in gestations when VOTra are well established (>28 weeks’ gestation) needs further evaluation.
Negative_regulation (prevention) of PTB associated with pre-term labor and infection
8) Confidence 0.17 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2861440 Disease Relevance 0.88 Pain Relevance 0.05
The combination of positive FFN test, and the transvaginal ultrasound scan (TVUSS) of women with a short cervical length (<30 mm) may identify those women who may benefit from interventions such as antibiotics and tocolytics which may reduce PTB.9–11

Infection and PTL

Negative_regulation (reduce) of PTB associated with infection
9) Confidence 0.11 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2861440 Disease Relevance 1.19 Pain Relevance 0.07

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox